BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19467582)

  • 21. Use and safety of antipsychotic drugs during pregnancy.
    Einarson A; Boskovic R
    J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic side effects of atypical antipsychotics in children: a literature review.
    Fedorowicz VJ; Fombonne E
    J Psychopharmacol; 2005 Sep; 19(5):533-50. PubMed ID: 16166191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Side effects as influencers of treatment outcome.
    Sharif Z
    J Clin Psychiatry; 2008; 69 Suppl 3():38-43. PubMed ID: 18533761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.
    Correll CU
    Int Rev Psychiatry; 2008 Apr; 20(2):195-201. PubMed ID: 18386212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment options for children and adolescents with bipolar disorder.
    Findling RL
    J Clin Psychiatry; 2009 Sep; 70(9):e34. PubMed ID: 19818240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of antipsychotics in children and adolescents.
    Kapetanovic S; Simpson GM
    Expert Opin Pharmacother; 2006 Oct; 7(14):1871-85. PubMed ID: 17020414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
    Byerly M; Suppes T; Tran QV; Baker RA
    J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of atypical antipsychotics in children: balancing safety and effectiveness.
    Kohlstadt I; Vitiello B
    Am Fam Physician; 2010 Mar; 81(5):585. PubMed ID: 20187594
    [No Abstract]   [Full Text] [Related]  

  • 29. [Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents a review of the literature and some recommendations'].
    Roke Y
    Tijdschr Psychiatr; 2010; 52(7):535-6; discussion 536. PubMed ID: 20623452
    [No Abstract]   [Full Text] [Related]  

  • 30. Polypharmacy with second-generation antipsychotics: a review of evidence.
    Pandurangi AK; Dalkilic A
    J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Second generation antipsychotics: similarities and differences].
    Jarema M; Rybakowski J; Landowski J
    Psychiatr Pol; 2003; 37(1):7-28. PubMed ID: 12685300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
    Moncrieff J
    Acta Psychiatr Scand; 2006 Jul; 114(1):3-13. PubMed ID: 16774655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing irritability and aggression in autism spectrum disorders in children and adolescents.
    Robb AS
    Dev Disabil Res Rev; 2010; 16(3):258-64. PubMed ID: 20981764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antipsychotics].
    Cattapan-Ludewig K; Seifritz E
    Ther Umsch; 2009 Jun; 66(6):402-6. PubMed ID: 19496035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dosing atypical antipsychotics.
    Cutler A; Ball S; Stahl SM
    CNS Spectr; 2008 May; 13(5 Suppl 9):1-16. PubMed ID: 18496483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term drug use in psychiatric disorders in children. Facts, controversies and the future.
    Werry JS
    Acta Paedopsychiatr; 1993; 56(2):113-8. PubMed ID: 7907832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of Hunperdal Richter in psychiatry].
    Magyar GI; Fadgyas I
    Neuropsychopharmacol Hung; 2009 Jun; 11(2):111-5. PubMed ID: 19827319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic drug toxicology in children.
    Caccia S; Clavenna A; Bonati M
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):591-608. PubMed ID: 21401439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of bipolar disorders and metabolic syndrome: implications for primary care.
    Bell PF; McKenna JP; Roscoe BM
    Postgrad Med; 2009 Sep; 121(5):140-4. PubMed ID: 19820282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.